据《中国医学论坛报》1999年5月27日报道,1999年2月4日刊载于美国《医学论坛报》的消息透露,最近FDA(美国食品与药物管理局)批准上市的品种有4个:(1)Cele-brex(通用名 Celecoxib,非类固醇类抗炎药,由美国Searls公司生产),用于治疗类风湿性关节炎和骨关节炎。本品对于能够引起上消化道溃疡的环氧化酶I没有抑制作用。(2)Ziagen(通用名abacavir sulfate,由Glaxo Wellcome公司生 According to the “China Medical Tribune” reported on May 27, 1999, the information published in the United States Medical Tribune on February 4, 1999 revealed that the FDA (US Food and Drug Administration) approved the listing of 4 : (1) Cele-brex (common name Celecoxib, a non-steroidal anti-inflammatory drug manufactured by Searls Company of the United States) for the treatment of rheumatoid arthritis and osteoarthritis. This product is able to cause upper gastrointestinal ulcer cyclooxygenase I did not inhibit the role. (2) Ziagen (generic name abacavir sulfate, produced by Glaxo Wellcome